We’re a company focused on tackling some of the toughest health challenges. Our success is reflected in our management team, which is individually and collectively focused on improving the lives of individuals who are faced with debilitating diseases. Our management team are leaders in their respective fields, including research, development and commercialization, to name a few.
President, North America and Global API
“We are inspired to provide product solutions for patients whose needs are not being fully addressed by treatments currently available. For decades, we have solved complex formulation, manufacturing and commercialization challenges, which has resulted in transformational medicines that address the needs of a changing healthcare industry and bring even greater benefits to partners and patients.”
Robert Matsuk is President of North America at Glenmark Pharmaceuticals. He is responsible for the company’s overall generics and branded pharmaceutical business across North America, as well as the Global API Business at Glenmark. Prior to joining Glenmark in 2014, he was Executive Vice President and Chief Strategy Officer at HighPoint Solutions, where he had overall responsibility for the Life Sciences business. He also held senior leadership positions within the Life Sciences industry at PricewaterhouseCoopers and Computer Sciences Corporation. He received his Master in Business Administration degree from the J.L. Kellogg Graduate School of Management at Northwestern University and graduated from the Philadelphia College of Pharmacy and Science with a Bachelor of Pharmacy degree.
Dr. Fred Grossman
President and Chief Medical Officer
“Drug discovery rarely occurs by any single, defined set of rules, nor does it always proceed as we would expect. Empowering our R&D staff in the context of a transparent, entrepreneurial culture where alternative approaches can be considered and implemented provides the ‘can do’ environment that motivates our staff, encourages debate and challenges our scientists and our clinicians.”
Dr. Fred Grossman, DO, FAPA, is President and Chief Medical Officer of Glenmark Pharmaceuticals. He oversees global clinical development, pharmacovigilance, medical affairs and clinical operations for innovative product development, as well as specialty and generic products. As President and Chief Medical Officer, he furthers Glenmark’s commitment to consistent investments in research that generates assets to address unmet medical needs in a variety of therapeutic areas. Dr. Grossman has more than 20 years of experience directing research and development for new potential medicines at leading, international pharmaceutical organizations. Before joining Glenmark in 2015, he held global medical leadership positions at Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb and Sunovion. Dr. Grossman is a board-certified physician, with a completed fellowship in pharmacology at the National Institutes of Health. He has several academic appointments and is the author of numerous scientific publications. He completed specialty training in psychiatry at Hahnemann University in Philadelphia.
President, Global Innovative Product Development
“With our dynamic R&D organization, we are accelerating the development of our medicines to fully realize the extraordinary potential of our diverse, innovative pipeline. Within the next five years, we have the momentum to introduce new products, built on cutting-edge science, which will provide meaningful difference for the patients we serve.”
Robert Jackson is the President of the Global Innovative Product Development Group at Glenmark Pharmaceuticals. He leads global product development in the innovation and specialty portfolio at Glenmark. Prior to joining Glenmark in 2015, he spent more than 30 years working in pharmaceutical research and development, which included leadership roles in global manufacturing, regulatory affairs, technical research and development, quality assurance, quality control and corporate project management and pre- and post-approval drug development for more than a dozen approved products in a variety of therapeutic areas at companies like Forest Laboratories Inc. and Novartis. He received his Master in Business Administration degree in pharmaceutical studies from Fairleigh Dickinson University in New Jersey and a Bachelor of Science degree in biochemistry from Lynchburg College in Virginia.
Our global executive leadership comprises the company’s top decision makers and is representative of the many countries in which we do business. Together, our leadership team is collectively focused on advancing Glenmark’s strategy and objectives. To learn more about our leadership team, click here.